Pyloric stenosis associated Crohn’s disease responding to adalimumab therapy

Gastroduodenal Crohn’s disease (CD) is rare and the response to standard medical therapy is often poor. Anti-tumor necrosis factor therapy has revolutionised the treatment of CD. We present a patient with pyloric stenosis associated with CD which improved with Adalimumab therapy. We recommend consid...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastrointestinal pharmacology and therapeutics Vol. 3; no. 6; pp. 97 - 99
Main Authors Gaggar, Sameer, Scott, John, Thompson, Nicholas
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 06.12.2012
Subjects
Case Report
disease;Anti-tumor
factor
necrosis
Pyloric
stenosis;Crohn’s
therapy;Adalimumab
Adalimumab
Pyloric stenosis
Anti-tumor necrosis factor therapy
Crohn’s disease
Online AccessGet full text

Cover

More Information
Summary:Gastroduodenal Crohn’s disease (CD) is rare and the response to standard medical therapy is often poor. Anti-tumor necrosis factor therapy has revolutionised the treatment of CD. We present a patient with pyloric stenosis associated with CD which improved with Adalimumab therapy. We recommend considering antitumor necrosis factor therapy in symptomatic gastroduodenal CD.
Bibliography:Sameer Gaggar, Nicholas Thompson, Department of Gastroenterology, Freeman Hospital, NE7 7DN Newcastle, United Kingdom John Scott, Department of Radiology, Freeman Hospital, NE7 7DN Newcastle, United Kingdom
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Gaggar S collected data and prepared manuscript; Scott J provided radiology data and input; Thompson N revised manuscript.
Correspondence to: Dr. Sameer Gaggar, Department of Gastroenterology, Freeman Royal Hospital, NE7 7DN Newcastle, United Kingdom. sameergaggar@nhs.net
ISSN:2150-5349
2150-5349
DOI:10.4292/wjgpt.v3.i6.97